Back to search

Article

Summary measures in non-inferiority clinical trials with a time-to-event outcome: an empirical comparison of power

2025-04-21

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold>: Time-to-event data is commonly used in non-inferiority clinical trials. While the hazard ratio is a popular summary measure in this context, the difference in restricted mean survival time has been theoretically shown to increase power and interpretability. This study aimed to empirically compare the power of the hazard ratio, difference in survival and differen...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1775c87c-f38c-5e7e-8673-84634acac633
DOI
10.21203/rs.3.rs-6171853/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Summary measures in non-inferiority clinical trials with a time-to-event outcome: an empirical comparison of powerDOI 10.21203/rs.3.rs-6171853/v1
Using Median Survival in Meta-analysis of Experimental Time-to-event DataSemantic proximity
An Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in OncologySemantic proximity
Restricted mean survival time approach versus time-varying coefficient Cox model for quantifying treatment effect when hazards are non-proportionalSemantic proximity
Review of calculation of conditional power, predictive power and probability of success in clinical trials with continuous, binary and time-to-event endpointsSemantic proximity
PROTOCOL: LLM-Generated CONSORT Report for Increased Reporting: A Parallel-Arm Randomized Controlled TrialSemantic proximity
The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitorsSemantic proximity
Examining the Feasibility and Functionality of Common Analysis Methods for Longitudinal Data with Binary OutcomesSemantic proximity
Statistical models to capture the association between progression-free and overall survival in oncology trialsSemantic proximity
Comparison of statistical methods for the analysis of patient-reported outcomes (PROs), particularly the Short-Form 36 (SF-36), in randomised controlled trials (RCTs) using standardised effect size (SES): an empirical analysisSemantic proximity
Statistics review 11: assessing risk.Semantic proximity
Randomized clinical trial quality has improved over time but is still not good enough: an analysis of 176,620 randomized controlled trials published between 1966 and 2018Semantic proximity
Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials.Semantic proximity
Select a neighboring publication to make it the new centre.